Charles River Laboratories International (NYSE:CRL) Price Target Cut to $173.00 by Analysts at Robert W. Baird

Charles River Laboratories International (NYSE:CRL) had its price target cut by research analysts at Robert W. Baird from $177.00 to $173.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price objective points to a potential upside of 4.85% from the stock’s current price.

A number of other brokerages have also commented on CRL. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Barclays decreased their price target on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Monday, February 3rd. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $196.43.

Charles River Laboratories International Trading Up 6.9 %

NYSE CRL opened at $165.00 on Thursday. The company has a market cap of $8.44 billion, a price-to-earnings ratio of 20.65, a price-to-earnings-growth ratio of 5.91 and a beta of 1.37. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The business’s fifty day moving average is $174.02 and its 200 day moving average is $188.99.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period last year, the firm posted $2.46 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International will post 10.16 EPS for the current fiscal year.

Institutional Trading of Charles River Laboratories International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after acquiring an additional 60,497 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. State Street Corp grew its position in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock worth $227,042,000 after buying an additional 14,787 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).